Ani Pharmaceuticals (ANIP) Return on Capital Employed (2012 - 2026)
Ani Pharmaceuticals (ANIP) posted Return on Capital Employed of 10.39% for Q1 2026, up 7.17% sequentially from 9.69% in Q4 2025, and up 979.0% YoY from 0.96% in Q1 2025.
Ani Pharmaceuticals (ANIP) Return on Capital Employed (2012 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Return on Capital Employed for 15 years, with the latest figure at 10.39% in Q1 2026.
- Quarterly Return on Capital Employed rose 979.0% year-over-year to 10.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.39% (up 979.0% YoY) and the FY2025 annual result came in at 10.25%, up 1018.0% from the prior year.
- Return on Capital Employed improved to 10.39% in Q1 2026 per ANIP's latest filing, from 9.69% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 10.39% in Q1 2026 and troughed at 9.17% in Q3 2022.
- A 5-year average of 1.45% and a median of 1.41% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 779 bps in 2022, then soared 1485 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 5.43% in 2022, then jumped by 215 bps to 6.25% in 2023, then tumbled by 99 bps to 0.05% in 2024, then surged by 18015 bps to 9.69% in 2025, then rose by 7 bps to 10.39% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 10.39%, 9.69%, and 6.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn | 12.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.80% |
| Mar 31, 2026 | 10.39% |
| Dec 31, 2025 | 9.69% |
| Sep 30, 2025 | 6.51% |
| Jun 30, 2025 | 1.41% |
| Mar 31, 2025 | 0.60% |
| Dec 31, 2024 | 0.05% |
| Sep 30, 2024 | 1.28% |
| Jun 30, 2024 | 6.45% |
| Mar 31, 2024 | 7.43% |
| Dec 31, 2023 | 6.25% |
| Sep 30, 2023 | 5.68% |
| Jun 30, 2023 | 2.77% |
| Mar 31, 2023 | -0.97% |
| Dec 31, 2022 | -5.43% |
| Sep 30, 2022 | -9.17% |
| Jun 30, 2022 | -9.11% |
| Mar 31, 2022 | -9.14% |
| Dec 31, 2021 | -7.46% |
| Sep 30, 2021 | -4.03% |